{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:20:17Z","timestamp":1791422417836,"version":"4.3.3"},"reference-count":67,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,5]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>First in human trial of Triplex vaccine shows safety and expansion of durable CMV-specific T cells with potential for viremia control. Triplex is immunogenic in both CMV-seronegative and -seropositive healthy adults with or without previous smallpox vaccination.<\/jats:p>","DOI":"10.1182\/blood-2016-07-729756","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T23:54:05Z","timestamp":1476921245000},"page":"114-125","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults"],"prefix":"10.1182","volume":"129","author":[{"given":"Corinna","family":"La Rosa","sequence":"first","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Longmate","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Beckman Research Institute of City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora I.","family":"Kaltcheva","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Drake","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Carroll","sequence":"additional","affiliation":[{"name":"Clinical Trial Office,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wussow","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Chiuppesi","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Hardwick","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet","family":"Dadwal","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Zaia","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111902373750800_B1","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"19","key":"2019111902373750800_B2","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111902373750800_B3","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111902373750800_B4","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1086\/508495","article-title":"Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients","volume":"194","author":"Lacey","year":"2006","journal-title":"J Infect Dis"},{"issue":"12","key":"2019111902373750800_B5","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.bbmt.2015.08.002","article-title":"Reconstitution of human cytomegalovirus-specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection","volume":"21","author":"Gabanti","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111902373750800_B6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/tid.12391","article-title":"Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation","volume":"17","author":"Gim\u00e9nez","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"2019111902373750800_B7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bmt.2010.330","article-title":"Reconstitution of CMV pp65 and IE-1-specific IFN-\u03b3 CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT","volume":"46","author":"Tormo","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111902373750800_B8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20420","article-title":"Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations","volume":"74","author":"Gratama","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2019111902373750800_B9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"2019111902373750800_B10","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"issue":"21","key":"2019111902373750800_B11","doi-asserted-by":"crossref","first-page":"47a","DOI":"10.1182\/blood.V124.21.47.47","article-title":"Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: A CIBMTR analysis [abstract]","volume":"124","author":"Ramanathan","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111902373750800_B12","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"issue":"2","key":"2019111902373750800_B13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2008.04.034","article-title":"A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector","volume":"377","author":"Wang","year":"2008","journal-title":"Virology"},{"issue":"11","key":"2019111902373750800_B14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2005.07.008","article-title":"Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection","volume":"11","author":"Gallez-Hawkins","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111902373750800_B15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects [published correction appears in J Exp Med. 2005;202(9):1301]","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"issue":"7","key":"2019111902373750800_B16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20042384","article-title":"Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells","volume":"201","author":"Bunde","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"2019111902373750800_B17","first-page":"322","article-title":"[Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine] [in German]","volume":"112","author":"Mayr","year":"1999","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"5-6","key":"2019111902373750800_B18","first-page":"375","article-title":"[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)]","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol [B]"},{"issue":"8","key":"2019111902373750800_B19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","article-title":"Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-na\u00efve and vaccinia-immune individuals","volume":"25","author":"Parrino","year":"2007","journal-title":"Vaccine"},{"issue":"9","key":"2019111902373750800_B20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1086\/651561","article-title":"Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration","volume":"201","author":"Wilck","year":"2010","journal-title":"J Infect Dis"},{"issue":"9","key":"2019111902373750800_B21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/651560","article-title":"Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax","volume":"201","author":"Seaman","year":"2010","journal-title":"J Infect Dis"},{"issue":"7","key":"2019111902373750800_B22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/CJI.0b013e3181ace876","article-title":"Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial","volume":"32","author":"Amato","year":"2009","journal-title":"J Immunother"},{"issue":"8","key":"2019111902373750800_B23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jgm.397","article-title":"Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer","volume":"5","author":"Rochlitz","year":"2003","journal-title":"J Gene Med"},{"issue":"17","key":"2019111902373750800_B24","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/1078-0432.CCR-13-3361","article-title":"p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses","volume":"20","author":"Hardwick","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111902373750800_B25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"2019111902373750800_B26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine"},{"issue":"33","key":"2019111902373750800_B27","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","article-title":"Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity","volume":"27","author":"Gudmundsdotter","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"2019111902373750800_B28","doi-asserted-by":"crossref","first-page":"e0141456","DOI":"10.1371\/journal.pone.0141456","article-title":"A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART","volume":"10","author":"G\u00f3mez","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"2019111902373750800_B29","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J Infect Dis"},{"issue":"6","key":"2019111902373750800_B30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.vaccine.2009.11.056","article-title":"Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines","volume":"28","author":"Wang","year":"2010","journal-title":"Vaccine"},{"issue":"1-2","key":"2019111902373750800_B31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0264-410X(02)00403-6","article-title":"Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya","volume":"21","author":"Hanke","year":"2002","journal-title":"Vaccine"},{"issue":"12","key":"2019111902373750800_B32","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.vaccine.2004.08.050","article-title":"Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice","volume":"23","author":"Hanke","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"2019111902373750800_B33","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/infdis\/jis107","article-title":"Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant [published correction appears in J Infect Dis. 2013;208(6):1038]","volume":"205","author":"La Rosa","year":"2012","journal-title":"J Infect Dis"},{"issue":"90","key":"2019111902373750800_B34","first-page":"1","article-title":"Infectious disease prevalence in Los Angeles county--a comparison to national estimates, 1999-2004 birth rates for U.S. teenagers reach historic lows for all age and ethnic groups","author":"Kruszon-Moran","year":"2012","journal-title":"NCHS Data Brief"},{"issue":"5","key":"2019111902373750800_B35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3201\/eid1005.030967","article-title":"Smallpox vaccination and adverse cardiac events","volume":"10","author":"Upfal","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"2019111902373750800_B36","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood.V90.5.1751","article-title":"Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection","volume":"90","author":"Diamond","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2019111902373750800_B37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cyto.a.20594","article-title":"Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities","volume":"73","author":"W\u00f6lfl","year":"2008","journal-title":"Cytometry A"},{"issue":"9","key":"2019111902373750800_B38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1432-2277.2011.01285.x","article-title":"Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients","volume":"24","author":"La Rosa","year":"2011","journal-title":"Transpl Int"},{"issue":"3","key":"2019111902373750800_B39","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2003-10-3469","article-title":"Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111902373750800_B40","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J Infect Dis"},{"issue":"8","key":"2019111902373750800_B41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/319680","article-title":"A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects","volume":"183","author":"Berencsi","year":"2001","journal-title":"J Infect Dis"},{"issue":"6","key":"2019111902373750800_B42","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/JVI.79.6.3675-3683.2005","article-title":"Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons","volume":"79","author":"Almanzar","year":"2005","journal-title":"J Virol"},{"issue":"18","key":"2019111902373750800_B43","doi-asserted-by":"crossref","first-page":"10894","DOI":"10.1128\/JVI.01477-14","article-title":"Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells","volume":"88","author":"Jackson","year":"2014","journal-title":"J Virol"},{"issue":"4","key":"2019111902373750800_B44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1086\/590118","article-title":"Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection","volume":"198","author":"Lilleri","year":"2008","journal-title":"J Infect Dis"},{"key":"2019111902373750800_B45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2019111902373750800_B46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.0105-2896.2010.00897.x","article-title":"Heterologous immunity between viruses","volume":"235","author":"Welsh","year":"2010","journal-title":"Immunol Rev"},{"issue":"3","key":"2019111902373750800_B47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1086\/505400","article-title":"A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis","volume":"43","author":"Crawford","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"39","key":"2019111902373750800_B48","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"2019111902373750800_B49","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.vaccine.2012.12.042","article-title":"Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery","volume":"31","author":"Meyer","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"2019111902373750800_B50","doi-asserted-by":"crossref","first-page":"e54407","DOI":"10.1371\/journal.pone.0054407","article-title":"Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review","volume":"8","author":"Elizaga","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2019111902373750800_B51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"},{"key":"2019111902373750800_B52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2172-9-9","article-title":"Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides","volume":"9","author":"Maecker","year":"2008","journal-title":"BMC Immunol"},{"issue":"9","key":"2019111902373750800_B53","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2009-06-227546","article-title":"Memories that last forever: strategies for optimizing vaccine T-cell memory","volume":"115","author":"Ahlers","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111902373750800_B54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/erv.09.160","article-title":"Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists","volume":"9","author":"Black","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"2019111902373750800_B55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"2019111902373750800_B56","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1128\/JVI.02654-06","article-title":"Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors","volume":"81","author":"Zhang","year":"2007","journal-title":"J Virol"},{"issue":"7","key":"2019111902373750800_B57","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.4049\/jimmunol.178.7.4455","article-title":"T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection","volume":"178","author":"Khan","year":"2007","journal-title":"J Immunol"},{"issue":"26","key":"2019111902373750800_B58","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111902373750800_B59","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2013.07.015","article-title":"CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome","volume":"19","author":"Sukdolak","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"242","key":"2019111902373750800_B60","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"285","key":"2019111902373750800_B61","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"2019111902373750800_B62","first-page":"62","article-title":"The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation","volume":"3","author":"Barrett","year":"2015","journal-title":"Ann Transl Med"},{"issue":"4","key":"2019111902373750800_B63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"issue":"4","key":"2019111902373750800_B64","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/JVI.75.4.1870-1878.2001","article-title":"Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes","volume":"75","author":"Marchini","year":"2001","journal-title":"J Virol"},{"issue":"1","key":"2019111902373750800_B65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/JVI.72.1.366-379.1998","article-title":"Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant","volume":"72","author":"Greaves","year":"1998","journal-title":"J Virol"},{"issue":"5","key":"2019111902373750800_B66","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.4049\/jimmunol.179.5.3203","article-title":"Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus","volume":"179","author":"Day","year":"2007","journal-title":"J Immunol"},{"issue":"9","key":"2019111902373750800_B67","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/1\/114\/1398610\/blood729756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/1\/114\/1398610\/blood729756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T16:07:22Z","timestamp":1601136442000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/1\/114\/35819\/MVA-vaccine-encoding-CMV-antigens-safely-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-729756","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726864531.793525796","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]}}}